Entheon Biomedical Corp. (CNSX:ENBI) acquired HaluGen Life Sciences Inc. for CAD 4.2 million on January 14, 2021. The company acquired 100% of the issued and outstanding common shares in the capital of HaluGen from the shareholders of HaluGen pursuant to a share exchange agreement, resulting in HaluGen becoming a wholly-owned subsidiary of Entheon. In consideration for the HaluGen Shares, the company issued an aggregate of 5.1 million common shares to the HaluGen shareholders which shall be released as follows: 1.275 million consideration shares on the closing of the acquisition; 1.275 million consideration shares four months following the closing date; 1.275 million consideration shares eight months following the closing date; and 1.275 million consideration shares twelve months following the closing date. Additionally, Entheon Biomedical may issue up to an additional 0.9 million common shares to Lobo Genetics Inc. in connection with a product development agreement dated November 13, 2020, as amended on January 14, 2021, among the company, HaluGen and Lobo. The issuance of the compensation shares is subject to Lobo fulfilling certain performance milestones in accordance with the terms of the Product Development Agreement. Entheon Biomedical Corp. (CNSX:ENBI) completed the acquisition of HaluGen Life Sciences Inc. on January 14, 2021.